More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age and older. The US affiliate of BTL Aesthetics has filed suit against Allergan and Germany’s Zimmer MedizinSysteme in the US Federal District Court for the District of Delaware, asserting that the Cooltone device infringes on BTL's US patents.
News | October 21, 2019
The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older....
News | October 18, 2019
Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of...
Ortho Dermatologics Launches Telemedicine on Dermatology.com, US Cash-Pay Prescription Program
Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acne
DermWireTV: Barbie Gets Inclusive, Hacking Prizes, Maui Derm Updates
Resident of Distinction Award Celebrates 10th Anniversary at 2020 Caribbean Dermatology Symposium